Bio2 Technologies, Inc.

Woburn, MA 02115, US
Medical Devices & Equipment

Bio2 is commercializing Vitrium, a novel biomaterial for use in orthopedic surgery. Vitrium fully resorbs while stimulating the remodeling of new, heathy bone. The first line of Vitrium products was recently cleared by the FDA.

Vitrium has broad application across a $50B global market. The application opportunities have pre-existing reimbursement and do not require modification of surgical techniques. The cost of manufacturing Vitrium products is at or below that of competitive technologies.

Future applications of Vitrium include cartilage regeneration, limb salvage and treatment of osteoporotic bone.
Bio2 currently has two active product development programs:
- Reconstructive surgery of the foot and ankle. Bio2 is currently releasing implants fours in the correction of flatfoot deformity and hammertoe repair.
- Spinal fusion. The final pre-clinical study for a cervical fusion device is in process with pitfall data expected in October 2016.

Our proprietary process is protective by a portfolio of issued patents in the US, Japan, China and Israel with patents pending in the EU.

Our management team has deep domain experience and a successful entrepreneurial track record in the orthopedics space. Bio2’s directors and advisors include veteran industry figures and recognized clinical and scientific thought leaders.

Our capital efficient business model seeks to drive IRR through engaging strategic partners across multiple sub-specialty market verticals. Investor capital is employed exclusively for product development, securing global regulatory approvals and manufacturing infrastructure.

General Information


Social Links

Company Industry

Select Industry:

Company Description

0 / 250
0 / 2000


Prior Year Revenue Current Year Revenue Next Year Revenue
Company Age Employees Sub-Industry
11 years, 9 months 7 Surgical

Company Financials

Viewable by EquityNet investors only

Company Age & Size


Products / Services

0 / 1000
Orthopedic Biomaterials/Implantable devices

Resorbable implants for use in reconstructive surgery, joint fusion and regenerative medicine.


0 / 1000
Paul K. Nichols Jr.

Paul K. Nichols Jr.Mr. Nichols has 40 years of experience with rapidly growing companies in the medical device industry, with the past 30 as an executive and entrepreneur in the musculoskeletal sector. Between 1995 and 2005 he was a founder and CEO of three orthopedic surgery technology companies with successful exits, the most recent being Nexa Orthopedics which was acquired by Tornier (NASD: TRNX) in 2007.

Chief Operating Officer
Janet Krevolin, Ph.D.

Janet Krevolin, Ph.D.Dr. Krevolin has over 25 years of experience in research and product development in the orthopedic surgery industry. Prior to joining Bio2, she held the position of Vice President, Global Product Development for Zimmer Holdings, Inc. (NYSE: ZMH). Prior responsibilities included the management of Zimmer’s European research activities. Dr. Krevolin has a doctorate in Mechanical Engineering from the University of Texas and a bachelor's degree from Wellesley College.

Vice President
Art O’Dea

Art O’DeaMr. O’Dea is responsible for managing quality assurance and legal affairs. Mr. O’Dea served as VP of Intellectual Property for GEO2 Technologies, where he built the patent portfolio relating to the CLM technology. Prior to GEO2, he was Patent Counsel for Cognex Corporation where he managed IP matters, including patent prosecution, patent litigation, and IP licensing. Mr. O’Dea has a BSME from the University of Vermont, an MS-CIM from BYU, and a JD from the Massachusetts School of Law. He is a member of the Massachusetts Bar and a registered Patent Attorney with the United States Patent and Trademark Office.



Funding Goal$2,000,000

Funding Raised So Far$1,300,000

Funding Commitments$225,000

Funding Remaining$475,000

Funding TypeEquity

Pre-Money Valuation

Investor Ownership

Interest / Dividend

Previous Funding

General Funding


Showing your General Funding information publicly may constitute general solicitation. General solicitation is a new commonly-used way for companies to raise funding. To learn about general solicitation, consult your legal counsel. If you uncheck this box, your General Funding information will be viewable to only EquityNet investors.

Private Funding

Viewable by EquityNet investors only


Bio2 Technologies, Inc. Image 1



Complete a Business Plan in EquityNet

Your EquityNet business plan is only viewable to capital providers and business supporters that you choose to share with in the “Crowdfund” or “Messages” tab. Investors prefer an EquityNet business plan. Entering a plan is highly educational and improves your appeal to investors.

Upload Documents

Document file names will be viewable by EquityNet investors and business supporters only. Actual documents are only viewable to capital providers and business supporters that you choose to share with in the “Crowdfund” or “Messages” tab.

Share Your Public Profile Page

Users who follow all these tips increase their fundraising odds substantially.

  • Email your public page to all your LinkedIn contacts.
    • Post your page to your LinkedIn profile page.
  • Email your public page to all your Facebook contacts.
    • Post your page to your Facebook profile page.
  • Email your public page to all your Twitter contacts.
    • Post your page to your Twitter profile page.
  • Put your public page up on your website.
    • Don't have a website yet? Use this page as your site!
  • Share your page link anywhere there's a listing for your company.
    • Press Releases, Crunchbase, Wikipedia, Blogs, etc...
  • Email your public page to all your email contacts.
    • Use Outlook, Gmail, Yahoo Mail, Hotmail, etc...

Your Public Profile Page:

Would you like to share your public profile page with your email contacts?